The new head of Dr. Martens is to reveal his strategy so that the boots manufacturer returns to the track in the middle of a sales fall.
The Camden -based footwear specialist will reveal his last annual results on Thursday, June 5, and a drop in income and profits is expected to publish.
However, investors are likely to focus on a company's strategy update that is also due that day.
The company's shares have fallen by more than 80% since it floated in the London stock market in early 2021.
The company has been ruined by sliding sales in recent years, since it has fought diminishing the demand for consumers and supply chain interruptions.
Ihe Nwokorie, former head of the business brand, assumed the main role in January in an attempt to help relive his fortune.
This week, the company also sought to strengthen its leadership team by appointing Carla Murphy of Adidas as its new brand director and former director of Nike Paul Zadofo as its president of America.
The appointments occur when Dr. Martens seeks to bring more buyers to the brand and aim at new growth opportunities.
Investte Kate Calvert analyst said: “Having assumed the position of CEO in January and knowing the company well (formerly brand director and non -executive director), we expect more than an evolutionary strategy.
“We are looking to hear what are the growth priorities of the equipment from a range of rank, market and channel, and understand the differences in the strategic approach of recent history.
“We also expect an update on the delivery of two crucial system projects: its client data platform plus a supply and demand planning system.”
Investec has predicted that the fashion firm will report revenues of approximately £ 803.5 million for the year until March 31.
It would represent another significant fall of £ 877.1 million the previous year.
In its previous update in January, Dr. Martens pointed out a partial recovery during the key festive period in the midst of progress to change its operation in the United States.
On Thursday, it is likely that the company shows greater progress with its direct business to the consumer, efforts to increase cost savings and strengthen its balance.
Susannah Streeter, director of money and markets at Hargreaves Lansdown, said: “Dr. Martens is expected to deliver more evidence that he is approaching with his boots and the change is tied together.
“It has reduced inventories and debt, preserving cash and stabilizing the business in general.
“So there is more optimism about Dr. Martens can start a more sustained recovery.”
Shareholders will also seek guidance on how their important business in the United States could be affected by recent changes in tariff rules and how the company could mitigate any impact.
